Stock PHAT PHATHOM PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Phathom Pharmaceuticals, Inc.

Equities

PHAT

US71722W1071

Delayed Nasdaq
Other stock markets
 16:00:00 2024-06-18 EDT 		5-day change 1st Jan Change
11.87 USD +1.45% Intraday chart for Phathom Pharmaceuticals, Inc. +7.62% +30.01%
06-11 Transcript : Phathom Pharmaceuticals, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 02:40 PM
05-09 Transcript : Phathom Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 09, 2024

Evolution of the average Target Price on Phathom Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

c7b0433a.53c7peqwPma_jwVECbkiS_ijIDhEYVjR13sCd0fq4P4.qCBCwoKFDw775GwVYMhUBMrRUE8MKDKJ4g00JSKhppW4J06TiYFOLc_qMQ~68bc257babcd36d6c19c8aa0c6f6d1ee

Analyst Recommendations on Phathom Pharmaceuticals, Inc.

Stifel Starts Phathom Pharmaceuticals With Buy Rating, $24 Price Target MT
Needham Raises Price Target on Phathom Pharmaceuticals to $26 From $23, Maintains Buy Rating MT
Goldman Sachs Adjusts Price Target on Phathom Pharmaceuticals to $10 From $9, Maintains Neutral Rating MT
HC Wainwright Initiates Coverage on Phathom Pharmaceuticals with Buy Rating, $28 Price Target MT
Craig-Hallum Starts Phathom Pharmaceuticals at Buy With $21 Price Target MT
BMO Capital Adjusts Price Target on Phathom Pharmaceuticals to $30 From $35, Maintains Outperform Rating MT
Needham Adjusts Price Target on Phathom Pharmaceuticals to $23 From $25, Maintains Buy Rating MT
BMO Capital Trims Price Target on Phathom Pharmaceuticals to $35 From $38, Affirms Outperform Rating MT
Needham Adjusts Phathom Pharmaceuticals Price Target to $25 From $38, Maintains Buy Rating MT
BMO Capital Cuts Price Target on Phathom Pharmaceuticals to $38 From $45, Maintains Outperform Rating MT
Guggenheim Adjusts Price Target on Phathom Pharmaceuticals to $30 From $42, Maintains Buy Rating MT
Jefferies Starts Phathom Pharmaceuticals at Buy With $16 Price Target MT
Needham Adjusts Phathom Pharmaceuticals' Price Target to $38 from $44, Keeps Buy Rating MT
Goldman Sachs Adjusts Price Target for Phathom Pharmaceuticals to $15 From $32, Retains Neutral Rating MT
PHATHOM PHARMACEUTICALS : Guggenheim Adjusts Phathom Pharmaceuticals PT to $75 From $66, Maintains Buy Rating MT
PHATHOM PHARMACEUTICALS : Goldman Sachs Upgrades Phathom Pharmaceuticals to Neutral From Sell, Adjusts Price Target to $48 From $40 MT
PHATHOM PHARMACEUTICALS : BMO Capital Starts Phathom Pharmaceuticals at Outperform With $63 Price Target MT
PHATHOM PHARMACEUTICALS : Guggenheim Starts Phathom Pharmaceuticals at Buy With $60 Price Target MT
PHATHOM PHARMACEUTICALS : Needham Adjusts Phathom Pharmaceuticals' Price Target to $55 from $45, Keeps Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
11.87 USD
Average target price
22.29 USD
Spread / Average Target
+87.75%
High Price Target
28 USD
Spread / Highest target
+135.89%
Low Price Target
10 USD
Spread / Lowest Target
-15.75%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Phathom Pharmaceuticals, Inc.

Stifel Nicolaus
Needham & Co.
Goldman Sachs
HC Wainwright
Craig-Hallum
BMO Capital
Guggenheim
Jefferies & Co.

Ratings for Phathom Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. PHAT Stock
  4. Consensus Phathom Pharmaceuticals, Inc.